WHO ICTRP trial
SAFETY AND TOLERABILITY OF ODM-201 IN PATIENTS WITH PROSTATE CANCER: EXTENSION…
EUCTR2010-022803-24-GB · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2010-022803-24-GB |
|---|---|
| Public title | SAFETY AND TOLERABILITY OF ODM-201 IN PATIENTS WITH PROSTATE CANCER: EXTENSION STUDY TO STUDY 3104001 |
| Scientific title | SAFETY AND TOLERABILITY OF ODM-201 IN PATIENTS WITH CASTRATE RESISTANT PROSTATE CANCER: OPEN, NON-RANDOMISED, UNCONTROLLED, MULTICENTRE, EXTENSION STUDY TO STUDY 3104001 - Arades-Ext Phase II |
| Primary sponsor | Orion Corporation Orion Pharma |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): yes Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): no |
| Countries | France;United States;Estonia;Czech Republic;Finland;United Kingdom |
| Conditions | Progressive castration resistant prostate cancer (MedDRA: hormone-refractory prostate cancer) MedDRA version: 14.1 Level: LLT Classification code 10062904 Term: Hormone-refractory prostate cancer System Organ Class: 10029104 - Neoplasms… |
| Interventions | Product Name: ODM-201 Product Code: ODM-201 Pharmaceutical Form: Capsule INN or Proposed INN: . Current Sponsor code: ODM-201 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- |
| Registration date | Nov 15, 2010 |
| Target size | 130 |
| Secondary IDs | 3104002 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- Yes Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: